Member Info for Saxondale

Think its in auction , but no chance of selling , as I'm still in the red until about £3 .
Hopefully not for long .
This went from 0-100 in 10 seconds

When I was a kid I always thought a polygon was a dead parrot .

https://www.polygoninv.com/

Steam rolling another slightly dubious drug onto the public at breakneck speed .
I'm sure the folk who haven't had a vaccine due to safety concerns are going to be queuing up for this one .
Participants of the trial must abstain from sex or use contraception , as worry over birth defects and cancer still hang over the drug .
Luckily , less than half of those trialed with the drug had any adverse reactions .
When can I get my hands on this wonder drug ?
https://www.drugdiscoverytrends.com/early-safety-concerns-accompanied-mercks-molnupiravir-the-first-potential-oral-covid-19-therapy/

Is it just me or do these Govt puppets give you no confidence whatsoever ?
If he says ' loved ones' one more time I may vomit .

Thought I'd found a piece on Synairgen today by Huffington Post .
Wow , they've got a new angle on todays story , I thought .
Then saw date was 2012 lol .
Still relevant though ??
https://www.huffingtonpost.co.uk/2012/04/20/astham-drug-breakthrough_n_1440209.html

I guess there are two factors , the dosing level , and the dosing frequency .
They discovered that they may need to increase the frequency to have a longer lasting effect on soluble clever 1 .
And Phase 2 is all about selecting the most effective dose for the next stages .
Perhaps as they have modified the protocols to increase frequency , they decided to test the dosing level to the max also , as its still well within its safety parameters .
Maybe they've seen something that points towards higher dosing , possibly doing that as a test on soluble clever 1 , as they were getting best results with mid range dosing levels i believe , or at least no great gains from higher dosing on the solid tumours .
Short answer I don't know .
But my hunch is that these changes have been made purely in order to test effects on soluble clever 1 .

Awesome indeed .
He can't stop smiling .
And for good reason .
To be a drug company that has a drug that can be deployed at home , hospital , and stockpiled , and be agnostic to variants is an envious position indeed .

The Bex trial got updated yesterday on Clinical website .

https://clinicaltrials.gov/ct2/show/NCT03733990?term=faron&draw=2&rank=3

1.)Dosing - a new arm ( so now 6 arms ) has been added with a 30mg/kg dose ( 3 times more than the max being trialed )
2.) Frequency - the 1,2,10,30 mg/kg arms all get dosing at 1,2 or 3 week intervals now , the other arms remain at 3 week .

This update reflects the additional testing for the effects of Bex on soluble Clever1 - which looks to require more frequent dosing , as levels were seen to rise again with such long doing intervals .

Great to see that they seem to thinks its safe to run with a dose of 30mg/kg - some 1000 times more than the lowest dose on the trial and triple the dose frequency at that level too .

Presumably this has been running for a while now , and they should be getting some data on these new dosing regimes .

Surely this milestone should warrant a RM interview on proactive to highlight what an achievement this is .

The home study was always going to be the harder one to prove - and it looks like they've done it , possibly by targeting the more breathless patients ( ie the ones in need ) .
Wow - I am so happy and relieved !!
I don't usually ramp - but this has to be huge .
A safe therapy - easy to administer at home - what price can you put on the company ?

Fantastic !

Pillock is also another much underused term of endearment . I always used to amuse myself in meetings , whenever i had to read the word 'analysis ' out aloud , I always pretended to stumble and read it as' Anal Isis' .
Pretty much summed up the company I used to work for anyway lol .

Hollmen Lab taken delivery of new digital spatial profiler tool .
GeoMX tool should really help with analysis of tumour data from the P2 cohorts I'd imagine .

Ideal for breast cancer anaysis - as noted on their website
https://www.nanostring.com/products/geomx-digital-spatial-profiler/geomx-dsp-overview/

Can't find an exact price - but pretty sure you won't get much change out of £250,000 .
Don't spill your coffee on this one !!

Indeed , it wouldn't have taken much to change the heading to ' Subcutaneous Interferon '
This is the NIH after all , not the Daily Mail .

What a bonus it is having such a relationship with Newcrest .
What many a junior explorer could only dream of .
Keep on drillin !

Another set of data on subcutaneous interferon ( Mercks drug , same one as used on the WHO Solidarity trial last year )
Shows no benefit over placebo when given with Remdesivir.
Something that Faron highlighted last year - subcutaneous is not an effective delivery method for getting enough Interferon to the lung cells .

So looks like big Pharma is going to have to look at Traumakine and SNG001 if they want an effective Interferon drug for Covid now .

https://www.nih.gov/news-events/news-releases/interferon-does-not-improve-outcomes-hospitalized-adults-covid-19?utm_source=dlvr.it&utm_medium=twitter

The WHO Solidarity trial proved that subcutaneous delivery was a waste of time last year .
Like others say - delivery method is key .
Nebulised , and to some extent I/V is the way to go .

Nice . And every time someone at GGP or Newcrest talks about Havieron , they always mention the 'next' Havieron .
Why do they keep talking like this .
Surely one Havieron is enough lol

IFN has been trialed by another company as treatment for organ failure ( intravenous IFN Beta1a ) .
https://clinicaltrials.gov/ct2/show/NCT03119701

It was stopped as they had complications caused by steroids ( as with the I/V trial on ARDS )
Both trials were run at a similar time , when they didn't know what was causing the issue ( steroids mainly , but the organ trial left much to be learnt )
https://www.researchsquare.com/article/rs-732466/v2

But given what they now know , IFN should in theory help with vascular issues and organ protection , it just needs to be given in the right situation and taking account of what other drugs are being used at the same time .

My take is that SNG001 is the better allround tool for COVID ,helping put IFN into the lungs given early via nebulizer , but given intravenously it may also be very effective ( without steroids ) , for patients whose lungs may have lost the proper function . I/V delivery may also help with vascular issues ( a big side symptom of Covid ) - due to the much higher dose entering the bloodstream . But it's the lack of lung function that may cause the organ failure in the first place , so if you can keep the lungs functioning , you hopefully help prevent it anyway .

That's my take on it , although I'm no expert .

Hopefully in time , both methods will be proven to be sound treatments .